Evidence map›Paper›PMID 20925577›Full record

ArticleJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics2010

Doxycycline hydrogels as a potential therapy for ocular vesicant injury.

Marion K Gordon, Andrea Desantis, Manjeet Deshmukh, Carl Jeffrey Lacey, Rita A Hahn, John Beloni, Sivanaga S Anumolu, John J Schlager, Michael A Gallo, Donald R Gerecke and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. BRD4 inhibition mitigates acute and chronic corneal injury following topical nitrogen mustard exposure.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Ocular Surface - Merging Challenges and Opportunities.Translational vision science & technology · 2020
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 3 countries.

Marion K GordonDepartment of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University , Piscataway, NJ 08854, USA. magordon@eohsi.rutgers.edu
Andrea Desantis
Manjeet Deshmukh
Carl Jeffrey Lacey
Rita A Hahn
John Beloni
Sivanaga S Anumolu
John J Schlager
Michael A Gallo
Donald R Gerecke
Ned D Heindel
Kathy K H Svoboda
Michael C Babin
Patrick J Sinko
Rutgers, The State University of New Jersey · USLehigh University · USBattelle · USJohnson University · USNovartis (Switzerland) · CHTexas A&M University System · USWright-Patterson Air Force Base · US

Funding

UMDNJ/Rutgers University CounterACT Research Center of ExcellenceU54AR055073 · NIAMS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI HECK, DIANE E · 2006 to 2024
$71.4M
Translational Research Support CoreP30ES005022 · NIEHS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI ROBERT John LAUMBACH · 1988 to 2026
$47.4M
REGULATION OF FIBRIL-ASSOCIATED COLLAGENS IN CORNEAR01EY009056 · NEI · TUFTS UNIVERSITY BOSTON · PI GORDON, MARION K · 1991 to 2010
$4.2M
NEI NIH HHS EY09056NEI NIH HHS R01 EY009056NIAMS NIH HHS U54AR055073NIEHS NIH HHS P30 ES005022NIEHS NIH HHS P30ES005022
6 · The paper itself

Abstract

purposeThe goals of this study were (1) to compare the injury at the basement membrane zone (BMZ) of rabbit corneal organ cultures exposed to half mustard (2 chloroethyl ethyl sulfide, CEES) and nitrogen mustard with that of in vivo rabbit eyes exposed to sulfur mustard (SM); (2) to test the efficacy of 4 tetracycline derivatives in attenuating vesicant-induced BMZ disruption in the 24-h period postexposure; and (3) to use the most effective tetracycline derivative to compare the improvement of injury when the drug is delivered as drops or hydrogels to eyes exposed in vivo to SM.

methodsHistological analysis of hematoxylin and eosin–stained sections was performed; the ultrastructure of the corneal BMZ was evaluated by transmission electron microscopy; matrix metalloproteinase-9 was assessed by immunofluorescence; doxycycline as drops or a hydrogel was applied daily for 28 days to eyes exposed in vivo to SM. Corneal edema was assessed by pachymetry and the extent of neovascularization was graded by length of longest vessel in each quadrant.

resultsInjury to the BMZ was highly similar with all vesicants, but varied in degree of severity. The effectiveness of the 4 drugs in retaining BMZ integrity did not correlate with their ability to attenuate matrix metalloproteinase-9 expression at the epithelial–stromal border. Doxycycline was most effective on organ cultures; therefore, it was applied as drops or a hydrogel to rabbit corneas exposed in vivo to SM. Eyes were examined at 1, 3, 7, and 28 days after exposure. At 7 and 28 days after SM exposure, eyes treated with doxycycline were greatly improved over those that received no therapy. Corneal thickness decreased somewhat faster using doxycycline drops, whereas the hydrogel formulation decreased the incidence of neovascularization.

conclusionsCorneal cultures exposed to 2-chloroethyl ethyl sulfide and nitrogen mustard were effective models to simulate in vivo SM exposures. Doxycycline as drops and hydrogels ameliorated vesicant injury. With in vivo exposed animals, the drops reduced edema faster than the hydrogels, but use of the hydrogels significantly reduced neovascularization. The data provide proof of principle that a hydrogel formulation of doxycycline as a daily therapy for ocular vesicant injury should be further investigated.

Indexed as

AnimalsAnti-Bacterial AgentsBasement MembraneCorneal DiseasesCorneal EdemaCorneal NeovascularizationDoxycyclineEpithelium, CornealEyeEye InjuriesHydrogelsIrritantsMaleMechlorethamineMustard GasNitrogen Mustard CompoundsAnti-Bacterial AgentsDoxycyclineHydrogelsIrritantsMechlorethamineMustard GasNitrogen Mustard CompoundsTetracyclines

Identifiers

PMID20925577
PMCPMC2956382
OpenAlexW2071833447

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.